View ValuationIDL Diagnostics 将来の成長Future 基準チェック /06現在、 IDL Diagnosticsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Life Sciences 収益成長20.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 30IDL Diagnostics AB (publ), Annual General Meeting, May 28, 2026IDL Diagnostics AB (publ), Annual General Meeting, May 28, 2026, at 11:00 W. Europe Standard Time. Location: company`s premises at karlsbodavagen 39 in bromma, Swedenお知らせ • Dec 16+ 1 more updateIDL Diagnostics AB (publ) to Report Q2, 2026 Results on Aug 20, 2026IDL Diagnostics AB (publ) announced that they will report Q2, 2026 results on Aug 20, 2026お知らせ • Nov 12IDL Diagnostics AB (publ) to Report Fiscal Year 2025 Final Results on Apr 22, 2026IDL Diagnostics AB (publ) announced that they will report fiscal year 2025 final results on Apr 22, 2026お知らせ • Oct 23IDL Diagnostics AB (publ) to Report Q3, 2025 Results on Nov 12, 2025IDL Diagnostics AB (publ) announced that they will report Q3, 2025 results on Nov 12, 2025お知らせ • May 07AroCell AB (publ) to Report Fiscal Year 2025 Results on Feb 24, 2026AroCell AB (publ) announced that they will report fiscal year 2025 results on Feb 24, 2026お知らせ • Apr 11Fredrik Lindgren Announces Not Stand for Re-Election to the Board of Arocell AB (Publ)AroCell AB (publ) announced Fredrik Lindgren has declined re-election to the board.お知らせ • Feb 19AroCell AB (publ) to Report Fiscal Year 2024 Final Results on Apr 11, 2025AroCell AB (publ) announced that they will report fiscal year 2024 final results on Apr 11, 2025お知らせ • Jan 09AroCell AB (publ) Announces CFO ChangesAroCell AB announced that Ellen Dittberner will return to her role as Chief Financial Officer (CFO) on January 13, 2025, after being on parental leave since February 2024. Ellen, who has previously played an important role in AroCell's financial development and strategic success, is now ready to resume her work and lead the company's financial function forward. During Ellen's parental leave, Lars Jakobsson has served as Acting CFO. Lars, with his extensive experience from both AroCell and IDL Biotech, has been an invaluable resource during this period.お知らせ • Jan 03Labbex Förvaltnings AB acquired additional 6.77% stake in AroCell AB (publ) (OM : AROC)Labbex Förvaltnings AB agreed to acquire additional 6.77% stake in AroCell AB (publ) (OM : AROC) on January 2, 2025. Post acquisition, Labbex Förvaltnings AB will hold 18.35 percent of the shares and votes in AroCell AB. Labbex Förvaltnings AB completed acquistion of additional 6.77% stake in AroCell AB (publ) (OM : AROC)お知らせ • Dec 18+ 2 more updatesAroCell AB (publ) to Report Q3, 2025 Results on Oct 23, 2025AroCell AB (publ) announced that they will report Q3, 2025 results on Oct 23, 2025New Risk • Nov 11New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.05m (US$9.64m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Market cap is less than US$10m (€9.05m market cap, or US$9.64m). Minor Risks Currently unprofitable and not forecast to become profitable next year (kr37m net loss next year). Revenue is less than US$5m (kr52m revenue, or US$4.8m).お知らせ • Oct 28AroCell Announces New Study Published on the Prognostic Value of sTK1 in Prostate CancerAroCell announced the publication of an important study in the European Urology Open Science journal. The study, led by Teemu Murtola at the University of Tampere in collaboration with scientists in Vienna and Budapest, reveals significant findings on the prognostic value of serum thymidine kinase 1 (sTK1) levels in patients with metastatic prostate cancer. Prostate cancer is the most common malignancy in men. While the Prostate Specific Antigen (PSA) serum biomarker is widely used for early detection of prostate cancer, it offers limited value for prediction of patient survival outcomes. Thymidine kinase 1 (TK1), an enzyme found in actively dividing cells, emerges as a crucial biomarker in this context. Different groups of patients with metastatic prostate cancer were studied with respect to the prognostic value of elevated levels of sTK1. High levels of sTK1 were associated with poor survival in patients with hormone-sensitive tumors treated with anti-hormone therapy. A more than 8-fold increased risk of death was associated with elevated sTK1, also after adjusting for age and other clinical factors, including PSA. A strong correlation between high sTK1 levels and reduced survival was also noted in castration-resistant prostate cancer patients. Interestingly, in patients treated with docetaxel (a chemotherapeutical drug), the association between sTK1 levels and survival was weaker compared to that observed for patients receiving androgen receptor signaling inhibitors. These results confirm previous findings of the potential of sTK1 as a prognostic biomarker. The findings suggest that sTK1 can be used to identify patients with disseminated prostate cancer that will benefit from chemotherapy rather than anti-hormonal treatment.Reported Earnings • Oct 26Third quarter 2024 earnings released: kr0.04 loss per share (vs kr0.056 loss in 3Q 2023)Third quarter 2024 results: kr0.04 loss per share (improved from kr0.056 loss in 3Q 2023). Revenue: kr14.0m (up 31% from 3Q 2023). Net loss: kr9.84m (loss narrowed 24% from 3Q 2023). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 22Second quarter 2024 earnings released: kr0.06 loss per share (vs kr0.067 loss in 2Q 2023)Second quarter 2024 results: kr0.06 loss per share (improved from kr0.067 loss in 2Q 2023). Revenue: kr15.3m (up 30% from 2Q 2023). Net loss: kr13.1m (loss narrowed 16% from 2Q 2023). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.お知らせ • May 05AroCell AB (publ) to Report Q2, 2024 Results on Aug 21, 2024AroCell AB (publ) announced that they will report Q2, 2024 results on Aug 21, 2024Reported Earnings • May 05First quarter 2024 earnings released: kr0.05 loss per share (vs kr0.059 loss in 1Q 2023)First quarter 2024 results: kr0.05 loss per share (improved from kr0.059 loss in 1Q 2023). Revenue: kr12.8m (up 16% from 1Q 2023). Net loss: kr10.5m (loss narrowed 23% from 1Q 2023). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.お知らせ • May 03AroCell AB (publ), Annual General Meeting, May 22, 2024AroCell AB (publ), Annual General Meeting, May 22, 2024.お知らせ • Apr 13AroCell AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025AroCell AB (publ) announced that they will report fiscal year 2024 results on Feb 19, 2025Buy Or Sell Opportunity • Apr 09Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 32% to €0.018. The fair value is estimated to be €0.023, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 78% over the last 3 years. Earnings per share has grown by 15%. Revenue is forecast to grow by 91% in 2 years. Earnings are forecast to grow by 46% in the next 2 years.Buy Or Sell Opportunity • Mar 12Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 33% to €0.019. The fair value is estimated to be €0.024, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 78% over the last 3 years. Earnings per share has grown by 15%. Revenue is forecast to grow by 91% in 2 years. Earnings are forecast to grow by 46% in the next 2 years.Reported Earnings • Feb 23Full year 2023 earnings released: kr0.26 loss per share (vs kr0.27 loss in FY 2022)Full year 2023 results: kr0.26 loss per share. Revenue: kr43.0m (up 16% from FY 2022). Net loss: kr59.3m (flat on FY 2022). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.お知らせ • Feb 23AroCell AB (publ) to Report Q3, 2024 Results on Oct 24, 2024AroCell AB (publ) announced that they will report Q3, 2024 results on Oct 24, 2024お知らせ • Feb 02AroCell AB (publ) Announces Chief Financial Officer ChangesAroCell AB (publ) announced that Ellen Dittberner will be on parental leave from her position as Chief Financial Officer (CFO) starting on February 1, 2024. During this period, Lars Jakobsson will serve as the acting CFO. Lars has previously held the position of CFO at IDL Biotech and AroCell AB from 2017 to 2022.Buying Opportunity • Jan 05Now 24% undervalued after recent price dropOver the last 90 days, the stock is down 25%. The fair value is estimated to be €0.035, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 91% over the last 3 years. Earnings per share has grown by 12%. Revenue is forecast to grow by 67% in 2 years. Earnings is forecast to grow by 37% in the next 2 years.Reported Earnings • Nov 03Third quarter 2023 earnings released: kr0.06 loss per share (vs kr0.048 loss in 3Q 2022)Third quarter 2023 results: kr0.06 loss per share (further deteriorated from kr0.048 loss in 3Q 2022). Revenue: kr10.7m (up 2.9% from 3Q 2022). Net loss: kr13.0m (loss widened 18% from 3Q 2022). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.New Risk • Oct 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.20m (US$9.72m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Market cap is less than US$10m (€9.20m market cap, or US$9.72m). Minor Risks Currently unprofitable and not forecast to become profitable next year (kr52m net loss next year). Revenue is less than US$5m (kr46m revenue, or US$4.1m).お知らせ • Sep 19AroCell AB (Publ) Announces New Study Highlights the Clinical Significance of TK1 SA for Early Detection of Ovarian CancerAroCell AB (publ) announced that its recent study on different clinical applications of the TK 210 ELISA in ovarian cancer has been accepted for publication in the Karger Oncology journal. The study focused on demonstrating the clinical utility of TK1-specific activity (TK1 SA) in the early detection of ovarian cancer. This study was conducted in collaboration with Professor Josko Osredkar and is titled "Clinical Significance of the TK1 specific Activity in the Early Detection of Ovarian Cancer". TK1 SA is determined by calculating the ratio of TK1 activity by TK-Liaison and TK1 protein by AroCell TK 210 ELISA. The study included 134 patients with ovarian tumors (72 benign and 62 malignant) and 64 healthy age-matched controls. The study results revealed that TK1 SA, which complements traditional biomarkers such as CA 125 and HE4, significantly improved the sensitivity for early detection of benign and malignant ovarian cancer. The combination of various biomarkers provided a more comprehensive and accurate diagnostic approach. These findings have implications in proving the early detection rates and subsequent treatment outcomes for ovarian cancer patients. Furthermore, the study observed the fluctuations in TK1 SA levels in relation to surgery and Chemotherapy which provided valuable information for monitoring the effectiveness of treatment and assessing disease progression.New Risk • Aug 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.16m (US$9.89m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Market cap is less than US$10m (€9.16m market cap, or US$9.89m). Minor Risks Currently unprofitable and not forecast to become profitable next year (kr52m net loss next year). Revenue is less than US$5m (kr46m revenue, or US$4.1m).Reported Earnings • Aug 23Second quarter 2023 earnings released: kr0.067 loss per share (vs kr0.069 loss in 2Q 2022)Second quarter 2023 results: kr0.067 loss per share (improved from kr0.069 loss in 2Q 2022). Revenue: kr11.8m (up 86% from 2Q 2022). Net loss: kr15.5m (loss narrowed 2.6% from 2Q 2022). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings.Reported Earnings • May 04First quarter 2023 earnings released: kr0.06 loss per share (vs kr0.091 loss in 1Q 2022)First quarter 2023 results: kr0.06 loss per share (improved from kr0.091 loss in 1Q 2022). Revenue: kr11.1m (up 42% from 1Q 2022). Net loss: kr13.7m (loss narrowed 12% from 1Q 2022). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.Reported Earnings • Feb 24Full year 2022 earnings released: kr0.28 loss per share (vs kr0.53 loss in FY 2021)Full year 2022 results: kr0.28 loss per share. Revenue: kr37.0m (up 208% from FY 2021). Net loss: kr59.0m (loss widened 18% from FY 2021). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.Board Change • Nov 16High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. Independent Director Eva Nordström is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Nov 02Third quarter 2022 earnings released: kr0.05 loss per share (vs kr0.15 loss in 3Q 2021)Third quarter 2022 results: kr0.05 loss per share (improved from kr0.15 loss in 3Q 2021). Revenue: kr10.4m (up 73% from 3Q 2021). Net loss: kr11.1m (loss narrowed 37% from 3Q 2021). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 19Second quarter 2022 earnings released: kr0.07 loss per share (vs kr0.089 loss in 2Q 2021)Second quarter 2022 results: kr0.07 loss per share. Revenue: kr6.35m (up kr6.32m from 2Q 2021). Net loss: kr15.9m (loss widened 136% from 2Q 2021). Over the next year, revenue is forecast to grow 46%, compared to a 13% growth forecast for the Life Sciences industry in Germany.お知らせ • Aug 18AroCell AB (publ) to Report Fiscal Year 2022 Results on Feb 23, 2023AroCell AB (publ) announced that they will report fiscal year 2022 results on Feb 23, 2023お知らせ • Jun 14AroCell Announced UBC® Rapid is Now Verified for Use on New InstrumentAroCell announces that quantitative point-of-care (POC) oncology product UBC Rapid has been verified for results interpretation on a new instrument, the Cube Reader. By differentiating UBC® Rapid and addressing the different needs of end-users, the possibility of a more widespread use increases. The Cube Reader is manufactured by the same company (Chembio Diagnostics Inc.) as the concile 100, which is currently exclusively used for interpretation of UBC® Rapid. The Cube Reader is a user-friendly, portable, palm-sized device that complements the concile 100 by better suiting simpler POC settings. Bladder Cancer has the higher lifetime treatment cost per patient due to a high likelihood of recurrence and long-term invasive follow-up. Unfortunately, the need for cost-effective, non-invasive, and simple POC tools to minimize the healthcare burden will increase due to a worldwide aging population. The use of UBC® Rapid would reduce this burden due to the versatility of its applications, both as an aid in diagnosis and during the long follow-up period.Board Change • Jun 02High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. Director Eva Nordström is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • May 13AroCell AB (publ) Announces New Clinical Study to Broaden the Use of TUBEX® TF on the African MarketAroCell AB (publ) announces that a new evaluation study of the TUBEX® TF product starts in Uganda. This study will be conducted in collaboration with the Uganda National Public Health Laboratory Services (UNHLS). The study is carried out for documentation of TUBEX® TF and will after a positive outcome work as a basis for market approval and sales. TUBEX® TF is a bacteriological rapid test for a simple and safe diagnosis of typhoid fever, the most serious form of salmonella. Typhoid fever is a water- and food-borne infectious disease that can be fatal if the correct diagnosis is not made and treatment is initiated. According to the WHO, 11 million 20 million new cases are diagnosed annually, of which more than 160,000 lead to deaths, mainly among children. Typhoid fever causes high fever, flu-like symptoms, and severe diarrhea, and is potentially life-threatening if not treated properly. Due to the symptoms, the patient may be misdiagnosed with diseases such as malaria, dengue fever, or pneumonia. As typhoid fever is treated with antibiotics and antibiotic resistance is, unfortunately, a growing problem, rapid testing, and correct diagnosis is a further argument for the need.Reported Earnings • May 03First quarter 2022 earnings released: kr0.09 loss per share (vs kr0.08 loss in 1Q 2021)First quarter 2022 results: kr0.09 loss per share (down from kr0.08 loss in 1Q 2021). Net loss: kr15.5m (loss widened 155% from 1Q 2021). Over the next year, revenue is forecast to grow 57%, compared to a 12% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings.Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Per-Anders Abrahamsson was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Apr 26AroCell AB (publ) Announces CFO ChangesEllen Dittberner will take over as Chief Finance Officer (CFO) at AroCell from August. Ellen replaces the current CFO, Lars Jakobsson, who will retire. Ellen has great experience, which includes driving change and development processes. Ellen has extensive experience in several different areas such as Group Accounting, Controlling, and Change Management. As CFO, Ellen will be responsible for AroCell Group's finances with associated processes and personnel. Lars Jakobsson will continue in his current role until Ellen takes office and thereafter continue to support AroCell in an advisory role as a consultant, to ensure the continuity of the AroCell Group's finance function and be responsible for a transfer to Ellen.Reported Earnings • Apr 08Full year 2021 earnings released: kr0.54 loss per share (vs kr0.33 loss in FY 2020)Full year 2021 results: kr0.54 loss per share (down from kr0.33 loss in FY 2020). Net loss: kr50.0m (loss widened 108% from FY 2020). Over the next year, revenue is forecast to grow 133%, compared to a 23% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.Board Change • Feb 04High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Per-Anders Abrahamsson was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Feb 03+ 4 more updatesAroCell AB (publ), Annual General Meeting, May 24, 2022AroCell AB (publ), Annual General Meeting, May 24, 2022.Reported Earnings • May 16First quarter 2021 earnings released: kr0.08 loss per share (vs kr0.086 loss in 1Q 2020)First quarter 2021 results: Net loss: kr6.08m (loss widened 11% from 1Q 2020).お知らせ • May 12AroCell AB (publ) (OM:AROC) agreed to acquire IDL Biotech AB (publ) for approximately SEK 240 million.AroCell AB (publ) (OM:AROC) agreed to acquire IDL Biotech AB (publ) for approximately SEK 240 million on May 10, 2021. Pursuant to the terms, AroCell AB (publ) will offer 0.63 shares for each shares in IDL Biotech AB (publ).Executive Departure • May 01Chief Commercial Officer has left the companyOn the 30th of April, Michael Brobjer's tenure as Chief Commercial Officer ended after less than a year in the role. We don't have any record of a personal shareholding under Michael's name. Michael is the only executive to leave the company over the last 12 months.Reported Earnings • Feb 21Full year 2020 earnings released: kr0.33 loss per share (vs kr0.53 loss in FY 2019)Full year 2020 results: Net loss: kr24.1m (loss widened 16% from FY 2019).お知らせ • Feb 18AroCell AB (publ), Annual General Meeting, May 06, 2021AroCell AB (publ), Annual General Meeting, May 06, 2021.Is New 90 Day High Low • Feb 18New 90-day high: €0.30The company is up 18% from its price of €0.25 on 19 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Life Sciences industry, which is up 19% over the same period.Is New 90 Day High Low • Jan 27New 90-day high: €0.29The company is up 46% from its price of €0.20 on 28 October 2020. The German market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 7.0% over the same period.お知らせ • Jan 20AroCell AB (publ) Appoints Gunnar Steineck as Chief Medical OfficerAroCell AB (publ) announced that Gunnar Steineck has been appointed Chief Medical Officer at AroCell. Gunnar has been a temporary CMO for five months and now takes the role permanently. Gunnar has extensive experience as an oncologist and clinical researcher. Gunnar Steineck has more than 35 years of experience in research in the medical field. After studying mathematics, statistics, and medicine at Uppsala University, he was trained as a specialist in oncology and radiation therapy at Karolinska University Hospital.お知らせ • Jan 12AroCell AB (publ) Appoints Anders Hultman as CEOAroCell AB (publ) announced a safe and smooth transition to a new CEO of the company. Former CFO Anders Hultman has been appointed new CEO. During the more than two years he has been at AroCell, Anders has done an exceptional job together with the former CEO Michael Brobjer, which enables a simple and smooth transition to the new role. Anders is very well acquainted with the company's strategies and plans to take the AroCell TK 210 ELISA to the next level. In addition to a solid experience as CFO, Anders has the business acumen needed for a demanding CEO assignment. He has previous experience of successfully running both listed and unlisted companies in various industries. Former CEO Michael Brobjer has resigned at his request. Michael resigns on 11 January 2021 as CEO and thus enables a smooth transition for the new CEO Anders Hultman.Is New 90 Day High Low • Oct 26New 90-day low: €0.26The company is down 1.0% from its price of €0.26 on 28 July 2020. The German market is also down 1.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Life Sciences industry, which is up 12% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、IDL Diagnostics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:80R - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/202655-8-5-5N/A12/31/202553-12-8-8N/A9/30/202552-49-7-6N/A6/30/202555-46-4-4N/A3/31/202560-4401N/A12/31/202457-42-3-2N/A9/30/202452-21-8-7N/A6/30/202448-34-9-8N/A3/31/202445-56-14-13N/A12/31/202343-59-15-13N/A9/30/202346-59-19-15N/A6/30/202346-57-15-11N/A3/31/202340-57-14-10N/A12/31/202237-59-18-14N/A9/30/202230-62-21-21N/A6/30/202226-69-27-26N/A3/31/202220-59-30-30N/A12/31/202112-50-29-28N/A9/30/20216-36-23-23N/A6/30/20210-25-21-21N/A3/31/20210-25-20-20N/A12/31/20200-24-19-19N/A9/30/20200-24-19-19N/A6/30/20200-22-16-16N/A3/31/20200-21-16-16N/A12/31/20190-21N/A-15N/A9/30/20190-20N/A-16N/A6/30/20190-21N/A-18N/A3/31/20191-22N/A-18N/A12/31/20181-21N/A-16N/A9/30/20181-21N/A-15N/A6/30/20181-19N/A-14N/A3/31/20180-17N/A-13N/A12/31/20171-17N/A-15N/A9/30/20170-13N/A-16N/A6/30/20170-12N/A-13N/A3/31/20170-11N/A-11N/A12/31/20160-9N/A-7N/A9/30/20161-9N/A-8N/A6/30/20160-8N/A-8N/A3/31/20160-8N/A-7N/A12/31/20150-7N/A-9N/A9/30/2015N/A-9N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 80Rの予測収益成長が 貯蓄率 ( 1.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 80Rの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 80Rの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 80Rの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 80Rの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 80Rの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 18:51終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋IDL Diagnostics AB (publ) 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Oscar BergmanRedeye
お知らせ • Apr 30IDL Diagnostics AB (publ), Annual General Meeting, May 28, 2026IDL Diagnostics AB (publ), Annual General Meeting, May 28, 2026, at 11:00 W. Europe Standard Time. Location: company`s premises at karlsbodavagen 39 in bromma, Sweden
お知らせ • Dec 16+ 1 more updateIDL Diagnostics AB (publ) to Report Q2, 2026 Results on Aug 20, 2026IDL Diagnostics AB (publ) announced that they will report Q2, 2026 results on Aug 20, 2026
お知らせ • Nov 12IDL Diagnostics AB (publ) to Report Fiscal Year 2025 Final Results on Apr 22, 2026IDL Diagnostics AB (publ) announced that they will report fiscal year 2025 final results on Apr 22, 2026
お知らせ • Oct 23IDL Diagnostics AB (publ) to Report Q3, 2025 Results on Nov 12, 2025IDL Diagnostics AB (publ) announced that they will report Q3, 2025 results on Nov 12, 2025
お知らせ • May 07AroCell AB (publ) to Report Fiscal Year 2025 Results on Feb 24, 2026AroCell AB (publ) announced that they will report fiscal year 2025 results on Feb 24, 2026
お知らせ • Apr 11Fredrik Lindgren Announces Not Stand for Re-Election to the Board of Arocell AB (Publ)AroCell AB (publ) announced Fredrik Lindgren has declined re-election to the board.
お知らせ • Feb 19AroCell AB (publ) to Report Fiscal Year 2024 Final Results on Apr 11, 2025AroCell AB (publ) announced that they will report fiscal year 2024 final results on Apr 11, 2025
お知らせ • Jan 09AroCell AB (publ) Announces CFO ChangesAroCell AB announced that Ellen Dittberner will return to her role as Chief Financial Officer (CFO) on January 13, 2025, after being on parental leave since February 2024. Ellen, who has previously played an important role in AroCell's financial development and strategic success, is now ready to resume her work and lead the company's financial function forward. During Ellen's parental leave, Lars Jakobsson has served as Acting CFO. Lars, with his extensive experience from both AroCell and IDL Biotech, has been an invaluable resource during this period.
お知らせ • Jan 03Labbex Förvaltnings AB acquired additional 6.77% stake in AroCell AB (publ) (OM : AROC)Labbex Förvaltnings AB agreed to acquire additional 6.77% stake in AroCell AB (publ) (OM : AROC) on January 2, 2025. Post acquisition, Labbex Förvaltnings AB will hold 18.35 percent of the shares and votes in AroCell AB. Labbex Förvaltnings AB completed acquistion of additional 6.77% stake in AroCell AB (publ) (OM : AROC)
お知らせ • Dec 18+ 2 more updatesAroCell AB (publ) to Report Q3, 2025 Results on Oct 23, 2025AroCell AB (publ) announced that they will report Q3, 2025 results on Oct 23, 2025
New Risk • Nov 11New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.05m (US$9.64m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Market cap is less than US$10m (€9.05m market cap, or US$9.64m). Minor Risks Currently unprofitable and not forecast to become profitable next year (kr37m net loss next year). Revenue is less than US$5m (kr52m revenue, or US$4.8m).
お知らせ • Oct 28AroCell Announces New Study Published on the Prognostic Value of sTK1 in Prostate CancerAroCell announced the publication of an important study in the European Urology Open Science journal. The study, led by Teemu Murtola at the University of Tampere in collaboration with scientists in Vienna and Budapest, reveals significant findings on the prognostic value of serum thymidine kinase 1 (sTK1) levels in patients with metastatic prostate cancer. Prostate cancer is the most common malignancy in men. While the Prostate Specific Antigen (PSA) serum biomarker is widely used for early detection of prostate cancer, it offers limited value for prediction of patient survival outcomes. Thymidine kinase 1 (TK1), an enzyme found in actively dividing cells, emerges as a crucial biomarker in this context. Different groups of patients with metastatic prostate cancer were studied with respect to the prognostic value of elevated levels of sTK1. High levels of sTK1 were associated with poor survival in patients with hormone-sensitive tumors treated with anti-hormone therapy. A more than 8-fold increased risk of death was associated with elevated sTK1, also after adjusting for age and other clinical factors, including PSA. A strong correlation between high sTK1 levels and reduced survival was also noted in castration-resistant prostate cancer patients. Interestingly, in patients treated with docetaxel (a chemotherapeutical drug), the association between sTK1 levels and survival was weaker compared to that observed for patients receiving androgen receptor signaling inhibitors. These results confirm previous findings of the potential of sTK1 as a prognostic biomarker. The findings suggest that sTK1 can be used to identify patients with disseminated prostate cancer that will benefit from chemotherapy rather than anti-hormonal treatment.
Reported Earnings • Oct 26Third quarter 2024 earnings released: kr0.04 loss per share (vs kr0.056 loss in 3Q 2023)Third quarter 2024 results: kr0.04 loss per share (improved from kr0.056 loss in 3Q 2023). Revenue: kr14.0m (up 31% from 3Q 2023). Net loss: kr9.84m (loss narrowed 24% from 3Q 2023). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 22Second quarter 2024 earnings released: kr0.06 loss per share (vs kr0.067 loss in 2Q 2023)Second quarter 2024 results: kr0.06 loss per share (improved from kr0.067 loss in 2Q 2023). Revenue: kr15.3m (up 30% from 2Q 2023). Net loss: kr13.1m (loss narrowed 16% from 2Q 2023). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.
お知らせ • May 05AroCell AB (publ) to Report Q2, 2024 Results on Aug 21, 2024AroCell AB (publ) announced that they will report Q2, 2024 results on Aug 21, 2024
Reported Earnings • May 05First quarter 2024 earnings released: kr0.05 loss per share (vs kr0.059 loss in 1Q 2023)First quarter 2024 results: kr0.05 loss per share (improved from kr0.059 loss in 1Q 2023). Revenue: kr12.8m (up 16% from 1Q 2023). Net loss: kr10.5m (loss narrowed 23% from 1Q 2023). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
お知らせ • May 03AroCell AB (publ), Annual General Meeting, May 22, 2024AroCell AB (publ), Annual General Meeting, May 22, 2024.
お知らせ • Apr 13AroCell AB (publ) to Report Fiscal Year 2024 Results on Feb 19, 2025AroCell AB (publ) announced that they will report fiscal year 2024 results on Feb 19, 2025
Buy Or Sell Opportunity • Apr 09Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 32% to €0.018. The fair value is estimated to be €0.023, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 78% over the last 3 years. Earnings per share has grown by 15%. Revenue is forecast to grow by 91% in 2 years. Earnings are forecast to grow by 46% in the next 2 years.
Buy Or Sell Opportunity • Mar 12Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 33% to €0.019. The fair value is estimated to be €0.024, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 78% over the last 3 years. Earnings per share has grown by 15%. Revenue is forecast to grow by 91% in 2 years. Earnings are forecast to grow by 46% in the next 2 years.
Reported Earnings • Feb 23Full year 2023 earnings released: kr0.26 loss per share (vs kr0.27 loss in FY 2022)Full year 2023 results: kr0.26 loss per share. Revenue: kr43.0m (up 16% from FY 2022). Net loss: kr59.3m (flat on FY 2022). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
お知らせ • Feb 23AroCell AB (publ) to Report Q3, 2024 Results on Oct 24, 2024AroCell AB (publ) announced that they will report Q3, 2024 results on Oct 24, 2024
お知らせ • Feb 02AroCell AB (publ) Announces Chief Financial Officer ChangesAroCell AB (publ) announced that Ellen Dittberner will be on parental leave from her position as Chief Financial Officer (CFO) starting on February 1, 2024. During this period, Lars Jakobsson will serve as the acting CFO. Lars has previously held the position of CFO at IDL Biotech and AroCell AB from 2017 to 2022.
Buying Opportunity • Jan 05Now 24% undervalued after recent price dropOver the last 90 days, the stock is down 25%. The fair value is estimated to be €0.035, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 91% over the last 3 years. Earnings per share has grown by 12%. Revenue is forecast to grow by 67% in 2 years. Earnings is forecast to grow by 37% in the next 2 years.
Reported Earnings • Nov 03Third quarter 2023 earnings released: kr0.06 loss per share (vs kr0.048 loss in 3Q 2022)Third quarter 2023 results: kr0.06 loss per share (further deteriorated from kr0.048 loss in 3Q 2022). Revenue: kr10.7m (up 2.9% from 3Q 2022). Net loss: kr13.0m (loss widened 18% from 3Q 2022). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.
New Risk • Oct 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.20m (US$9.72m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Market cap is less than US$10m (€9.20m market cap, or US$9.72m). Minor Risks Currently unprofitable and not forecast to become profitable next year (kr52m net loss next year). Revenue is less than US$5m (kr46m revenue, or US$4.1m).
お知らせ • Sep 19AroCell AB (Publ) Announces New Study Highlights the Clinical Significance of TK1 SA for Early Detection of Ovarian CancerAroCell AB (publ) announced that its recent study on different clinical applications of the TK 210 ELISA in ovarian cancer has been accepted for publication in the Karger Oncology journal. The study focused on demonstrating the clinical utility of TK1-specific activity (TK1 SA) in the early detection of ovarian cancer. This study was conducted in collaboration with Professor Josko Osredkar and is titled "Clinical Significance of the TK1 specific Activity in the Early Detection of Ovarian Cancer". TK1 SA is determined by calculating the ratio of TK1 activity by TK-Liaison and TK1 protein by AroCell TK 210 ELISA. The study included 134 patients with ovarian tumors (72 benign and 62 malignant) and 64 healthy age-matched controls. The study results revealed that TK1 SA, which complements traditional biomarkers such as CA 125 and HE4, significantly improved the sensitivity for early detection of benign and malignant ovarian cancer. The combination of various biomarkers provided a more comprehensive and accurate diagnostic approach. These findings have implications in proving the early detection rates and subsequent treatment outcomes for ovarian cancer patients. Furthermore, the study observed the fluctuations in TK1 SA levels in relation to surgery and Chemotherapy which provided valuable information for monitoring the effectiveness of treatment and assessing disease progression.
New Risk • Aug 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.16m (US$9.89m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Market cap is less than US$10m (€9.16m market cap, or US$9.89m). Minor Risks Currently unprofitable and not forecast to become profitable next year (kr52m net loss next year). Revenue is less than US$5m (kr46m revenue, or US$4.1m).
Reported Earnings • Aug 23Second quarter 2023 earnings released: kr0.067 loss per share (vs kr0.069 loss in 2Q 2022)Second quarter 2023 results: kr0.067 loss per share (improved from kr0.069 loss in 2Q 2022). Revenue: kr11.8m (up 86% from 2Q 2022). Net loss: kr15.5m (loss narrowed 2.6% from 2Q 2022). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 55% per year, which means it is significantly lagging earnings.
Reported Earnings • May 04First quarter 2023 earnings released: kr0.06 loss per share (vs kr0.091 loss in 1Q 2022)First quarter 2023 results: kr0.06 loss per share (improved from kr0.091 loss in 1Q 2022). Revenue: kr11.1m (up 42% from 1Q 2022). Net loss: kr13.7m (loss narrowed 12% from 1Q 2022). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.
Reported Earnings • Feb 24Full year 2022 earnings released: kr0.28 loss per share (vs kr0.53 loss in FY 2021)Full year 2022 results: kr0.28 loss per share. Revenue: kr37.0m (up 208% from FY 2021). Net loss: kr59.0m (loss widened 18% from FY 2021). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe.
Board Change • Nov 16High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. Independent Director Eva Nordström is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Nov 02Third quarter 2022 earnings released: kr0.05 loss per share (vs kr0.15 loss in 3Q 2021)Third quarter 2022 results: kr0.05 loss per share (improved from kr0.15 loss in 3Q 2021). Revenue: kr10.4m (up 73% from 3Q 2021). Net loss: kr11.1m (loss narrowed 37% from 3Q 2021). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 19Second quarter 2022 earnings released: kr0.07 loss per share (vs kr0.089 loss in 2Q 2021)Second quarter 2022 results: kr0.07 loss per share. Revenue: kr6.35m (up kr6.32m from 2Q 2021). Net loss: kr15.9m (loss widened 136% from 2Q 2021). Over the next year, revenue is forecast to grow 46%, compared to a 13% growth forecast for the Life Sciences industry in Germany.
お知らせ • Aug 18AroCell AB (publ) to Report Fiscal Year 2022 Results on Feb 23, 2023AroCell AB (publ) announced that they will report fiscal year 2022 results on Feb 23, 2023
お知らせ • Jun 14AroCell Announced UBC® Rapid is Now Verified for Use on New InstrumentAroCell announces that quantitative point-of-care (POC) oncology product UBC Rapid has been verified for results interpretation on a new instrument, the Cube Reader. By differentiating UBC® Rapid and addressing the different needs of end-users, the possibility of a more widespread use increases. The Cube Reader is manufactured by the same company (Chembio Diagnostics Inc.) as the concile 100, which is currently exclusively used for interpretation of UBC® Rapid. The Cube Reader is a user-friendly, portable, palm-sized device that complements the concile 100 by better suiting simpler POC settings. Bladder Cancer has the higher lifetime treatment cost per patient due to a high likelihood of recurrence and long-term invasive follow-up. Unfortunately, the need for cost-effective, non-invasive, and simple POC tools to minimize the healthcare burden will increase due to a worldwide aging population. The use of UBC® Rapid would reduce this burden due to the versatility of its applications, both as an aid in diagnosis and during the long follow-up period.
Board Change • Jun 02High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. No highly experienced directors. Director Eva Nordström is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • May 13AroCell AB (publ) Announces New Clinical Study to Broaden the Use of TUBEX® TF on the African MarketAroCell AB (publ) announces that a new evaluation study of the TUBEX® TF product starts in Uganda. This study will be conducted in collaboration with the Uganda National Public Health Laboratory Services (UNHLS). The study is carried out for documentation of TUBEX® TF and will after a positive outcome work as a basis for market approval and sales. TUBEX® TF is a bacteriological rapid test for a simple and safe diagnosis of typhoid fever, the most serious form of salmonella. Typhoid fever is a water- and food-borne infectious disease that can be fatal if the correct diagnosis is not made and treatment is initiated. According to the WHO, 11 million 20 million new cases are diagnosed annually, of which more than 160,000 lead to deaths, mainly among children. Typhoid fever causes high fever, flu-like symptoms, and severe diarrhea, and is potentially life-threatening if not treated properly. Due to the symptoms, the patient may be misdiagnosed with diseases such as malaria, dengue fever, or pneumonia. As typhoid fever is treated with antibiotics and antibiotic resistance is, unfortunately, a growing problem, rapid testing, and correct diagnosis is a further argument for the need.
Reported Earnings • May 03First quarter 2022 earnings released: kr0.09 loss per share (vs kr0.08 loss in 1Q 2021)First quarter 2022 results: kr0.09 loss per share (down from kr0.08 loss in 1Q 2021). Net loss: kr15.5m (loss widened 155% from 1Q 2021). Over the next year, revenue is forecast to grow 57%, compared to a 12% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 47% per year, which means it is significantly lagging earnings.
Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Per-Anders Abrahamsson was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 26AroCell AB (publ) Announces CFO ChangesEllen Dittberner will take over as Chief Finance Officer (CFO) at AroCell from August. Ellen replaces the current CFO, Lars Jakobsson, who will retire. Ellen has great experience, which includes driving change and development processes. Ellen has extensive experience in several different areas such as Group Accounting, Controlling, and Change Management. As CFO, Ellen will be responsible for AroCell Group's finances with associated processes and personnel. Lars Jakobsson will continue in his current role until Ellen takes office and thereafter continue to support AroCell in an advisory role as a consultant, to ensure the continuity of the AroCell Group's finance function and be responsible for a transfer to Ellen.
Reported Earnings • Apr 08Full year 2021 earnings released: kr0.54 loss per share (vs kr0.33 loss in FY 2020)Full year 2021 results: kr0.54 loss per share (down from kr0.33 loss in FY 2020). Net loss: kr50.0m (loss widened 108% from FY 2020). Over the next year, revenue is forecast to grow 133%, compared to a 23% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.
Board Change • Feb 04High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Per-Anders Abrahamsson was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 03+ 4 more updatesAroCell AB (publ), Annual General Meeting, May 24, 2022AroCell AB (publ), Annual General Meeting, May 24, 2022.
Reported Earnings • May 16First quarter 2021 earnings released: kr0.08 loss per share (vs kr0.086 loss in 1Q 2020)First quarter 2021 results: Net loss: kr6.08m (loss widened 11% from 1Q 2020).
お知らせ • May 12AroCell AB (publ) (OM:AROC) agreed to acquire IDL Biotech AB (publ) for approximately SEK 240 million.AroCell AB (publ) (OM:AROC) agreed to acquire IDL Biotech AB (publ) for approximately SEK 240 million on May 10, 2021. Pursuant to the terms, AroCell AB (publ) will offer 0.63 shares for each shares in IDL Biotech AB (publ).
Executive Departure • May 01Chief Commercial Officer has left the companyOn the 30th of April, Michael Brobjer's tenure as Chief Commercial Officer ended after less than a year in the role. We don't have any record of a personal shareholding under Michael's name. Michael is the only executive to leave the company over the last 12 months.
Reported Earnings • Feb 21Full year 2020 earnings released: kr0.33 loss per share (vs kr0.53 loss in FY 2019)Full year 2020 results: Net loss: kr24.1m (loss widened 16% from FY 2019).
お知らせ • Feb 18AroCell AB (publ), Annual General Meeting, May 06, 2021AroCell AB (publ), Annual General Meeting, May 06, 2021.
Is New 90 Day High Low • Feb 18New 90-day high: €0.30The company is up 18% from its price of €0.25 on 19 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Life Sciences industry, which is up 19% over the same period.
Is New 90 Day High Low • Jan 27New 90-day high: €0.29The company is up 46% from its price of €0.20 on 28 October 2020. The German market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 7.0% over the same period.
お知らせ • Jan 20AroCell AB (publ) Appoints Gunnar Steineck as Chief Medical OfficerAroCell AB (publ) announced that Gunnar Steineck has been appointed Chief Medical Officer at AroCell. Gunnar has been a temporary CMO for five months and now takes the role permanently. Gunnar has extensive experience as an oncologist and clinical researcher. Gunnar Steineck has more than 35 years of experience in research in the medical field. After studying mathematics, statistics, and medicine at Uppsala University, he was trained as a specialist in oncology and radiation therapy at Karolinska University Hospital.
お知らせ • Jan 12AroCell AB (publ) Appoints Anders Hultman as CEOAroCell AB (publ) announced a safe and smooth transition to a new CEO of the company. Former CFO Anders Hultman has been appointed new CEO. During the more than two years he has been at AroCell, Anders has done an exceptional job together with the former CEO Michael Brobjer, which enables a simple and smooth transition to the new role. Anders is very well acquainted with the company's strategies and plans to take the AroCell TK 210 ELISA to the next level. In addition to a solid experience as CFO, Anders has the business acumen needed for a demanding CEO assignment. He has previous experience of successfully running both listed and unlisted companies in various industries. Former CEO Michael Brobjer has resigned at his request. Michael resigns on 11 January 2021 as CEO and thus enables a smooth transition for the new CEO Anders Hultman.
Is New 90 Day High Low • Oct 26New 90-day low: €0.26The company is down 1.0% from its price of €0.26 on 28 July 2020. The German market is also down 1.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Life Sciences industry, which is up 12% over the same period.